Balyasny Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Balyasny Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-700	Closed	-$278K	–	2847
2025 Q4	$278K	Buy	+700	New	+$310K	﹤0.01%	2757
2025 Q2	–	Sell	-2,600	Closed	-$702K	–	2765
2025 Q1	$702K	Buy	+2,600	New	+$668K	﹤0.01%	2145
2024 Q4	–	Sell	-10,600	Closed	-$2.92M	–	2691
2024 Q3	$2.92M	Buy	+10,600	New	+$2.76M	﹤0.01%	1507
2023 Q1	–	Sell	-29,100	Closed	-$6.92M	–	2602
2022 Q4	$6.92M	Hold	29,100	–	–	0.02%	889
2022 Q3	$5.83M	Buy	+29,100	New	+$5.55M	0.02%	922
2022 Q2	–	Sell	-56,000	Closed	-$9.14M	–	2714
2022 Q1	$9.14M	Sell	56,000 -42,000	-43%	-$6.4M	0.03%	728
2021 Q4	$16.6M	Buy	+98,000	New	+$18.2M	0.06%	483
2021 Q3	–	Sell	-169,000	Closed	-$28.6M	–	1901
2021 Q2	$28.6M	Buy	+169,000	New	+$24.8M	0.14%	199
2020 Q4	–	Sell	-50,000	Closed	-$7.28M	–	1287
2020 Q3	$7.28M	Sell	50,000 -55,000	-52%	-$7.82M	0.05%	488
2020 Q2	$15.6M	Buy	+105,000	New	+$14.2M	0.13%	232
2019 Q4	–	Sell	-50,000	Closed	-$4.02M	–	1143
2019 Q3	$4.02M	Buy	+50,000	New	+$3.96M	0.03%	592
2018 Q4	–	Sell	-194,000	Closed	-$18.4M	–	1362
2018 Q3	$18.4M	Buy	+194,000	New	+$19.5M	0.08%	323
2018 Q2	–	Sell	-287,500	Closed	-$34.2M	–	1755
2018 Q1	$34.2M	Buy	+287,500	New	+$37.1M	0.14%	200

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's ALNY Position: Q1 2026 in Review

Balyasny Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3,026 shares — an estimated $1.2M sold.

Balyasny Asset Management first reported a position in ALNY in Q2 2015 and held it in 24 quarters. The position peaked at $50.4M in Q1 2023. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Balyasny Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 3,026 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.2M.
Balyasny Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 24 quarters.
Balyasny Asset Management's Alnylam Pharmaceuticals position peaked at $50.4M in Q1 2023.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.